Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) serves as a notification of the submission of its Annual Report on Form 20-F for the fiscal year ended December 31, 2012. The filing was made with the SEC on March 8, 2013, and this specific Form 6-K was signed on March 11, 2013.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It references the existence of audited financial statements within the linked Form 20-F but does not summarize the figures within this document.
Material Changes
No material changes or comparative financial data versus prior periods are detailed in this filing. The document acts solely as a procedural announcement regarding the availability of the 2012 Annual Report.
Guidance, Outlook, and Risks
- Forward-Looking Statements: GSK includes a cautionary statement noting that any projections are subject to risks and uncertainties that may cause actual results to differ materially.
- Risk Factors: Specific operational risks are referenced as being detailed under Item 3.D "Risk factors" in the 2012 Annual Report on Form 20-F.
- Shareholder Information: Shareholders may receive email notifications via www.shareview.co.uk or request hard copies of the audited financial statements through registrars in the UK, The Bank of New York Mellon, or the GSK Response Center in the USA.
Investor Verification Checklist
- Verify the full audited financial statements for the year ended December 31, 2012, by accessing the Form 20-F on the SEC website or GSK's corporate reporting portal.
- Review Item 3.D "Risk factors" in the Form 20-F for detailed operational risks not summarized here.
- Confirm the availability of the Notice of Annual General Meeting, expected to be available on or about March 20, 2013.